Valeant Announces 2017 Annual Meeting Results

LAVAL, Quebec, May 3, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today the election of the ten directors nominated at its 2017 annual meeting of shareholders held on May 2, 2017. The detailed results of the vote for the election of directors are set out below:

Name


For


Withheld


Broker Non-Votes










Richard U. DeSchutter


123,623,109


5,319,736


98,872,954


Dr. Frederic N. Eshelman


126,125,069


2,817,776


98,872,954


D. Robert Hale


123,127,211


5,815,634


98,872,954


Dr. Argeris (Jerry) N. Karabelas


123,529,948


5,412,897


98,872,954


Sarah B. Kavanagh


126,292,442


2,650,403


98,872,954


Joseph C. Papa


123,983,101


4,959,744


98,872,954


Robert N. Power


125,649,938


3,292,907


98,872,954


Russel C. Robertson


126,590,227


2,352,618


98,872,954


Thomas W. Ross, Sr.


126,166,299


2,776,546


98,872,954


Amy B. Wechsler, M.D.


123,473,243


5,469,602


98,872,954


At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation and an annual frequency of advisory votes on the compensation of our named executive as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2018 annual meeting of shareholders.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site at www.valeant.com.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Elif McDonald
elif.mcdonald@valeant.com         
514-856-3855
877-281-6642 (toll free)

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

 

SOURCE Valeant Pharmaceuticals International, Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890